February 17th 2025
The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma.
Elranatamab Shows Efficacy of BCMA-Targeted Therapy in Multiple Myeloma
January 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MagnetisMM-1 and MagnetisMM-3 trials of elranatamab in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.
Read More
Quadruplet Trials Form New Standard in Transplant-Eligible Multiple Myeloma
January 9th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the GRIFFIN and MASTER trials in patients with newly diagnosed multiple myeloma, as well as the phase 3 Perseus trial. This is the second of 2 articles based on this event.
Read More
Isatuximab-Based Triplet Therapy Improves Outcomes in R/R Multiple Myeloma
January 4th 2024In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.
Read More
Teclistamab Shows Strong Efficacy in Triple-Refractory Multiple Myeloma
December 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. This is the first of 2 articles based on this event.
Read More